Clinical trial
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL)…
NCT00050999 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00050999 |
|---|---|
| Title | Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients |
| Official title | A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or… |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome |
| Intervention type | Drug |
| Interventions | ONTAK |
| Enrollment | 195 |
| Start date | Jun 1, 1995 |
| Primary completion | Sep 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Jan 3, 2003 |
| Last update posted | Mar 5, 2008 |
| Countries | Australia, Austria, Canada, Germany, Netherlands, Poland, Russia, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: